Recent studies have shown that the activation of TLR1/2 signaling enhances the antitumor efficacy of CTLA-4 blockade, suggesting that TLR1/2 signaling participates in not only innate immunity against bacterial infection but also adaptive immunity to eradicate tumor cells. Here, TLR1 is linked to bacterial infectious disease.